🇺🇸 FDA

Company profile · Sponsor

Arcturus

Arcturus Therapeutics Holdings

ARCT · NYSE pharma SAN DIEGO, CA, USA
Pipeline
13
Drugs
0
Patents
8

Quick answer

Arcturus (ARCT) is a pharma company. headquartered in SAN DIEGO, CA, USA. listed on NYSE. NovaPharmaNews links 13 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker ARCT
Exchange NYSE
Company type pharma
Headquarters SAN DIEGO, CA, USA
SEC CIK 0001768224

Pipeline (13)

Search pipeline →

  1. ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine

    Arcturus

    COVID-19 Vaccines

    phase 3 mab completed

    1 trial

  2. ARCT-2303

    Arcturus

    COVID-19

    phase 3 mab completed

    1 trial

  3. A Phase 2, Open-label, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Efficacy of ARCT-032 in People with Cystic Fibrosis

    Arcturus

    Cystic Fibrosis

    phase 2 other active

    1 trial

  4. ARCT-021

    Arcturus

    SARS-CoV-2

    phase 2 mab terminated

    1 trial

  5. ARCT-021 Dose 1

    Arcturus

    SARS-CoV-2

    phase 2 mab completed

    1 trial

  6. ARCT-021 single dose priming

    Arcturus

    Covid19

    phase 2 mab terminated

    1 trial

  7. ARCT-032

    Arcturus

    Cystic Fibrosis

    phase 2 small molecule active

    2 trials

  8. ARCT-165

    Arcturus

    COVID-19

    phase 2 mab completed

    1 trial

  9. ARCT-810

    Arcturus

    Ornithine Transcarbamylase Deficiency

    phase 2 mab completed

    3 trials

  10. ARCT-810

    Arcturus

    OTC Deficiency

    phase 2 mab active

    1 trial

  11. SARS-CoV-2 mRNA Vaccine ARCT-021

    Arcturus

    Hematopoietic and Lymphatic System Neoplasm

    phase 2 mab active

    1 trial

  12. ARCT-2138

    Arcturus

    Influenza, Human

    phase 1 mab completed

    1 trial

  13. ARCT-2304

    Arcturus

    Influenza, Human

    phase 1 mab completed

    1 trial

Patents (8)

Search patents →

  1. US 12398379

    Compositions and methods for treating ornithine transcarbamylase deficiency

    Expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12390524

    Compositions and methods for inducing immune responses

    Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12351834

    Compositions and methods for the treatment of ornithine transcarbamylase deficiency

    Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12290567

    Asialoglycoprotein Receptor mediated delivery of therapeutically active conjugates

    Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12286395

    Method of synthesis of an ionizable cationic lipid

    Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12220455

    Coronavirus vaccine compositions and methods

    Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12220485

    Method of making lipid-encapsulated RNA nanoparticles

    Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12178921

    Method of lyophilizing lipid nanoparticles

    Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Arcturus?

Arcturus (ARCT) is a pharma company. headquartered in SAN DIEGO, CA, USA. listed on NYSE. NovaPharmaNews links 13 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Arcturus sponsor?

We track 13 ClinicalTrials.gov-linked programs for Arcturus, including ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine and 12 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Arcturus company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.